Adriana Fandiño | Universidad de Buenos Aires (original) (raw)

Uploads

Papers by Adriana Fandiño

Revista Mexicana de Oftalmología, Sep 9, 2022

Journal of ophthalmology and research, 2021

Revista Mexicana de Oftalmología (English Edition)

Oman Journal of Ophthalmology, Apr 8, 2022

A 6-year-old girl with visual impairment in the right eye (OD) was referred for an eye evaluation... more A 6-year-old girl with visual impairment in the right eye (OD) was referred for an eye evaluation. The fundus of the OD showed a fibrotic orange endophytic lesion located adjacent to the optic disc. In retinal optical coherence tomography, a local tractional retinal detachment and choroidal neovascular membrane were observed together also with the presence of subretinal fluid. Due to the vision of the OD evolved to nonlight perception in the following exam, enucleation was performed. The pathology report was correlated with hemangioblastoma. Herein, we describe a case of a young girl with a retinal hemangioblastoma with quick evolution and without prior systemic diagnosis.

Indian Journal of Ophthalmology - Case Reports, 2021

Revista Mexicana de Oftalmología, 2021

Archivos de la Sociedad Española de Oftalmología, 2020

Pediatric Blood & Cancer, 2018

Patients with retinoblastoma and central nervous system (CNS) involvement are rarely curable with... more Patients with retinoblastoma and central nervous system (CNS) involvement are rarely curable with available treatments. We designed a high-dose intra-arterial regimen targeting the ophthalmic artery and chiasm combined with intrathecal chemotherapy to treat a 4-year-old patient with retinoblastoma metastasized to the CNS. After three cycles of this regimen, including carboplatin, melphalan, and intrathecal topotecan, a partial response of the orbital tumor mass and chiasmatic lesion, and complete response in the cerebrospinal fluid and bone marrow were achieved. This new treatment strategy may be explored as a treatment component for patients with overt extraocular retinoblastoma and CNS dissemination.

Journal of Pediatric Hematology/Oncology, 2006

RESUMEN Objetivo: Descripción de una técnica original para el tratamiento de retinoblastoma ocula... more RESUMEN Objetivo: Descripción de una técnica original para el tratamiento de retinoblastoma ocular avanzado. Materiales y método: 820 sesiones de quimioinfusión intra arterial superselectiva en 176 pacientes pediátricos fueron analizadas. Describimos la técnica 2 en 2 pasos para cateterización oftálmica, su utilidad, seguridad y eficacia principalmente para primeras sesiones de quimiocirugía. Resultados: La primer quimioinfusión de Argentina fue en junio 2010 y hasta junio 2021 fueron realizadas 820 sesiones (4.6 sesiones por paciente). En todos los casos la arteria oftálmica pudo ser cateterizada (535 directamente y 285 por arteria meníngea media) con una opacificación coroidea aceptable. Se utilizó un abordaje femoral 3 F en 83% de los casos (pacientes <15 meses), microcatéter Marathon® 1.5 y Magic 1.5 y 1.2 en el 78%. Tiempo de fluoroscopía en primera sesión entre 0:41 y 4:13 min en tumores unilaterales, 1:12 y 7:34 en bilaterales. No se observaron complicaciones relacionadas con la técnica. Conclusión: Es una técnica simple, segura y con excelentes resultados. Permite la posibilidad de realizar quimiocirugía en pacientes pediátricos con poca instrumentación y sin la necesidad de utilizar acceso 4 F, catéteres guía ni microbalones.

Journal of Clinical Oncology, May 1, 1996

To describe the treatment of retinoblastoma at a single institution using a prospective protocol ... more To describe the treatment of retinoblastoma at a single institution using a prospective protocol based on histopathologic staging. We included 116 consecutive patients (101 eligible, 46 bilateral) from August 1987 to December 1993. Treatment was enucleation or conservative therapy for intraocular disease (stage I patients). Stage II patients (orbital or postlaminar invasion) received vincristine, cyclophosphamide, and doxorubicin for 57 weeks. Patients with orbital mass and extension beyond the cut end of the optic nerve also received orbital radiotherapy (45 Gy). The latter received intrathecal therapy. In those with CNS (stage III) or hematogenous metastasis (stage IV), cisplatin and etoposide were added along with cranial (in patients with a CNS mass and prophylactically in stage IV) or craniospinal (in patients with positive CSF) radiotherapy. The median follow-up time was 39 months (range, 12 to 84). The overall survival rate was 0.84. Survival rates according to stage were as follows: stage I probability of overall survival [pOS] = 0.97) (alive/total), 59 of 60; stage II (pOS = 0.85) including patients with scattered episcleral cells, three of three; orbital mass, one of one; postlaminar invasion up to and beyond the cut end of optic nerve, 10 of 11 and 11 of 14, respectively; of stage III (pOS = 0), zero of six; and stage IV (pOS = 0.50), three of six. Only those patients with preauricular adenopathy as the only metastatic site survived in the latter group. Acute toxicity was mild. Chemotherapy is not warranted to prevent systemic metastasis for intraocular disease. Patients with extraocular orbital disease and had a good outcome with this therapy. Patients with metastatic disease fared poorly, except for those with isolated malignant preauricular adenopathy.

Journal of Global Oncology, Dec 1, 2016

Retinoblastoma is a highly curable neoplasm in the developed world. 1 In less-developed countries... more Retinoblastoma is a highly curable neoplasm in the developed world. 1 In less-developed countries, however, survival figures are lower mostly because of delayed diagnosis and poor treatment compliance. 2 During the past decades, in middleincome countries, disease-free survival of children with retinoblastoma has improved gradually, but there are many challenges related with advanced disease at diagnosis that introduce specific considerations for management. 3,4 In that setting, children present with more advanced intraocular disease that frequently needs enucleation and systemic treatment to prevent extraocular dissemination; occasionally, they present with metastatic disease that needs high-dose therapy. 2 Unlike many other pediatric malignancies, medical evidence needed for the treatment of these children is not available from cooperative groups from higher-income countries (HICs), simply because this condition is virtually nonexistent in HICs and because limited results have been reported by cooperative groups. Thus, evidence is left to be generated in less-developed countries. In addition, eye-conservative treatment is a challenge in this setting, not only because more patients present with more advanced disease but also because of the relatively low availability of sophisticated therapies and training of specialized personnel to use local treatments. 5

Pediatric Blood & Cancer

BackgroundRetinoblastoma survivors in low‐ and middle‐income countries are exposed to high‐intens... more BackgroundRetinoblastoma survivors in low‐ and middle‐income countries are exposed to high‐intensity treatments that potentially place them at higher risk of early subsequent malignant neoplasms (SMNs).MethodsWe followed 714 (403 [56.4%] nonhereditary and 311 [43.5%] hereditary) retinoblastoma survivors diagnosed from August 1987 to December 2016, up to the age of 16 years. We quantified risk of SMNs with cumulative incidence (CI) and standardized incidence ratios (SIR) analysis. Multivariate regression Cox model was used to determine the association of treatments and risk of SMNs.ResultsMedian follow‐up was of 9 years (range: 0.18–16.9) and 24 survivors (3.36%) developed 25 SMNs (n = 22 hereditary, n = 2 nonhereditary). SMNs included sarcomas (osteosarcomas, Ewing sarcomas, rhabdomyosarcomas; n = 12), leukemias (n = 5), and central nervous system tumors (CNS; n = 3). All cases of acute myeloid leukemia (AML) and most of Ewing sarcomas occurred within 5 years of retinoblastoma diagn...

Investigative Ophthalmology & Visual Science, 2007

Investigative Ophthalmology & Visual Science, 2011